Threshold Pharmaceuticals Inc., a development-stage biotechnology company, said late Thursday its third-quarter loss widened on higher research, development, and interest expenses.
The company lost $6.2 million, or 40 cents per share, compared with a loss of $4.6 million, or 49 cents per share, during the year-ago period.
Threshold reported no revenue, compared with $362,000 a year prior.
Operating expenses rose 4 percent to $5.2 million as the company continued developing its potential cancer treatment TH-302. Meanwhile, interest expense surged to $957,000 from $13,000.
